Clinical Trials Logo

PNH clinical trials

View clinical trials related to PNH.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05884060 Completed - Thrombosis Clinical Trials

Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones

Start date: April 20, 2018
Phase:
Study type: Observational

The present study is a non-interventional retrospective chart review study assessing the prevalence of PNH-clones in patients with PNH risk-factors aged ≥14 years and treated at our hospital. The objective of this study is to develop a PNH screening tool on the hospital Electronic Health Record (EHR) system. An algorithm defining PNH risk groups is developed.

NCT ID: NCT05337683 Completed - PNH Clinical Trials

A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean PNH Patients

Start date: December 11, 2020
Phase:
Study type: Observational

This study is a retrospective chart review study, and the main objective of this study is to identify the impact of eculizumab treatment and the improvement of complications before and after eculizumab treatment, and to evaluate the safety during the treatment and the clinical unmet needs during the treatment in PNH patients in real-world.

NCT ID: NCT05095168 Completed - PNH Clinical Trials

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects

Start date: February 22, 2021
Phase: Phase 1
Study type: Interventional

This is a single site, single dose escalation study in healthy subject with CAN106. The study is to assess the safety and tolerability of single escalating doses of CAN106; to characterize the PK and PD profile of CAN106; and to evaluate the immunogenicity of CAN106 injection.

NCT ID: NCT03593200 Completed - PNH Clinical Trials

A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

Start date: August 16, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase IIa, open-label, multiple dose, study in patients with PNH who have not received eculizumab (Soliris ®) in the past. A single cohort of subjects is planned for evaluation.

NCT ID: NCT02605993 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: January 4, 2016
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of multiple intravenous (IV) doses of ravulizumab administered to complement inhibitor treatment-naïve participants with PNH.

NCT ID: NCT02598583 Completed - PNH Clinical Trials

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: November 12, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluated the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple intravenous (IV) doses of ALXN1210 administered to participants with PNH who have not previously been treated with complement inhibitor.

NCT ID: NCT01412047 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

Start date: March 2012
Phase: N/A
Study type: Observational

How does long term treatment with Soliris affect HAHA in PNH patients?